Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair

Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Matthew Fust, a veteran finance executive in the life sciences industry, to its Board of Directors. Mr. Fust will also serve as chair of the Audit Committee.

“We are pleased to welcome Matthew as a member of our board at this exciting time of growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics. “Matthew’s deep leadership experience will bring important strategic, financial, and operational perspectives across the Star family of companies.”

“It is a privilege to be joining the Star Therapeutics board as the company continues to be an innovation engine, discovering and advancing promising new antibody therapeutics into the clinic,” said Mr. Fust. “I’m looking forward to working with the Board and the Star Therapeutics team to continue the significant progress they have achieved to date.”

For over 20 years, Mr. Fust has served as a director of private and public biopharmaceutical companies, and he currently is a director on the boards of Atara Biotherapeutics, Crinetics Pharmaceuticals, Neumora Therapeutics, and Ultragenyx Pharmaceuticals. Previously, Mr. Fust served as Chief Financial Officer for a number of biopharmaceutical companies including Onyx Pharmaceuticals, Jazz Pharmaceuticals, and ALZA Corporation, and was a consultant in Andersen Consulting’s healthcare strategy practice. Mr. Fust holds an undergraduate degree in accounting from the University of Minnesota, and an MBA from the Stanford University Graduate School of Business.

“Matthew is an industry veteran with numerous successes in his career,” said Beth Seidenberg, MD, Founding Managing Director at Westlake Village BioPartners. “We look forward to his many contributions as we continue to advance numerous life-changing therapies for patients.”

About Star Therapeutics

Star Therapeutics is a biotechnology company that interrogates areas of novel biology to develop life-changing therapies for as many patients as possible, initially addressing unmet needs in hematology and immunology. The company’s engine for innovation starts with identifying multiple diseases that share a common biology and then discovering novel therapeutics that can treat numerous diseases with a single therapy. Star consists of a constellation of companies, each focused on a specific area of biology with first-in-class therapies. Star is backed by leading life sciences investors and located in South San Francisco. For more information, please visit https://star-therapeutics.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205606102/en/